The biologics market is booming, and shifting fast
The global biologics market is surging, valued at $457 billion in 2023, and is expected to grow at a robust 10–15% rate annually. Monoclonal antibodies (mAbs) still dominate, accounting for 45–55% of all approved biologics, with strong traction in oncology and immunology.
However, real acceleration is happening in next-generation therapies. Cell and gene therapies, along with RNA-based treatments, are at the forefront of innovation, especially for rare diseases. Global spending on these advanced therapies is expected to triple from $10 billion to $33 billion by 2028, making them the fastest-growing segment.
Therapeutic focus is also evolving. Oncology remains a hotbed for innovation, but there is a noticeable shift from rare to prevalent cancers. Meanwhile, diabetes and obesity are seeing explosive interest, with new mechanisms of action expanding beyond traditional GLP-1 drugs.
New modalities are rapidly entering the biopharma pipeline as they allow huge innovation potential in curing critical and rare diseases. As biosimilars gain regulatory traction and the pipeline for RNA, cell, and gene therapies expands, biologics are no longer a niche—they are mainstream.
This shift creates massive demand for excipients and processing ingredients but intensifies pressure on suppliers to stay ahead. The winners will be those who understand ingredient needs before they hit peak demand, build responsive supply chains, and tailor solutions to evolving modalities and formulations.
What’s missing in the market? A clear view of ingredient demand for specialty chemicals suppliers
Growth in biologics brings complexity, especially for specialty ingredients and excipients suppliers.
Biologics are expensive and intricate as they can cost 20x more to develop than small molecules. With each new modality comes unique demands for high-purity and highly specialized ingredients.
Yet, for suppliers trying to align with this growth, critical questions remain unanswered:
- Which excipients are used in which biologics?
- In what quantities, purities, or grades are they used?
- At which stage in manufacturing or delivery are they used?
- For what drug types, modalities, and routes of administration are they used?
Without reliable, integrated data, ingredient suppliers are left to piece together scattered information, making it hard to plan, forecast, and compete effectively.
What’s available today? Not much that connects the dots to showcase opportunity
The existing data on FDA approvals, clinical trials, and sales figures is fragmented and disconnected from excipient and ingredient use. There is no clear benchmark that links drug pipelines to the excipients used across biologics production stages—let alone by modality or route of administration.
This information gap means:
- Missed opportunities for ingredient customization
- Risk of under- or over-supplying key components
- Delays in aligning with biopharma innovation cycles
Kline can become your biologics intelligence partner, a reliable and complete data provider
At Kline, we offer an information pool for the success of specialty chemicals suppliers in the biologics marketplace. Our expert team offers comprehensive insights into and strategic guidance for analyzing the much-needed information:
- A commercial biologics drug database, structured for ingredient mapping
- Decoded sales and pipeline data, aligned with bioprocessing and formulation needs
- Integrated insights into dosage forms, modalities, routes of administration, and excipient functionality
- Competitive analysis combined with excipient market dynamics
- Ongoing updates and predictive models tied to industry news and drug approvals
Introducing the Kline’s Biologics Mapping Tool, offering a competitive edge in a rapidly evolving market
Kline’s Biologics Mapping Tool is a way to connect the dots from biologics drugs to ingredients and excipients in a meaningful market assessment.
With deep expertise in market research, digital analytics, and the pharma value chain, Kline developed a dynamic, data-driven solution tailored specifically for specialty chemical suppliers in the biologics space.
Kline’s Biologics Mapping Tool is an interactive, smart platform designed to give ingredient suppliers a strategic edge in a fast-evolving market.
It offers:
- An easily navigable dashboard with filters that allow users to analyze the data by production stage, modality, route of administration, and functionality
- Data downloads and forecast tools for deeper assessment, with or without pipeline overlays
- Quarterly pipeline analysis: An ongoing feed of updates based on clinical trial activity and new approvals
It is a decision-making engine that turns fragmented data into focused strategy and helps align with market needs, forecast demand, and stay ahead of the innovation curve.
Whether it is optimizing supply chains, planning ingredient portfolios, or looking for new commercial opportunities, Kline’s Biologics Mapping Tool is the blueprint for success.
Kline + Company is a global market intelligence and advisory firm with core competencies in the Energy, Chemicals, and Beauty sectors. Kline empowers clients to make informed decisions that drive business growth with an unparalleled depth of industry expertise, extensive research capabilities, and data-driven insights.
